RPG Life Sciences Limited , a leading integrated pharmaceutical company, has announced its unaudited financial results for the second quarter and first half of the fiscal year 2026, ending September 30, 2025. The company reported growth in revenue and profit, alongside the resignation of its Chief Financial Officer.

Financial Highlights

RPG Life Sciences demonstrated financial performance in Q2 FY26:

The company's revenue from operations grew by 5.50% year-on-year to Rs. 18168.00 lakhs in Q2 FY26. Despite a decrease in EBITDA, RPG Life Sciences reported an increase in profit before tax and profit after tax, primarily due to exceptional items.

Segment Performance

• Domestic Formulations: This segment contributed 71% to the total sales in H1 FY26, delivering growth.
• International Formulations: Accounting for 19% of total sales, this segment saw improvements in new products, customers, and markets contributions.
• API (Active Pharmaceutical Ingredients): Contributing 10% to total sales, this segment's growth was impacted by a fire incident in one of the manufacturing blocks earlier in the year.

Exceptional Items

The company reported exceptional income of Rs. 1122.00 lakhs in Q2 FY26, related to insurance proceeds from a fire incident that occurred at one of its manufacturing blocks in January 2025. This contributed to the increased profitability for the quarter.

CFO Resignation

RPG Life Sciences announced the resignation of its Chief Financial Officer, Mr. Vishal Shah, effective October 23, 2025. Mr. Shah cited personal reasons for his departure. The company stated that it is in the process of identifying a suitable replacement for the CFO position.

Management Initiatives

The company's investor presentation highlighted several strategic initiatives:

• Focus on building mega brands and expanding product portfolios
• Emphasis on sustainable operations and ESG initiatives
• Continued efforts in digitalization and innovation projects
• Expansion of global presence with capex infusion

Outlook

RPG Life Sciences appears positioned for future growth, with a focus on chronic and specialty therapies, expansion of its global footprint, and investments in plant upgrades and capacity expansion. The company's debt-free status and improved credit rating underscore its financial stability.

RPG Life Sciences , a leading integrated pharmaceutical company, has announced ambitious plans to expand its presence in the over-the-counter (OTC) pharmaceutical market while reporting its financial results for the first quarter.

Strategic Expansion into OTC Market

The company has revealed its strategic intent to target the ₹500 crore OTC pharmaceutical market in India. As part of this initiative, RPG Life Sciences plans to invest ₹200 crore specifically in immunosuppressant drugs, signaling a strong commitment to this therapeutic area. This move is expected to strengthen the company's position in the growing OTC segment and complement its existing portfolio.

Focus on Global Generics

In addition to its OTC market expansion, RPG Life Sciences is placing emphasis on global generics as a key component of its long-term growth strategy. This focus on international markets aligns with the company's vision to become a more globally oriented pharmaceutical player.

Q1 Financial Performance

For the quarter ended June 30, RPG Life Sciences reported the following financial results:

The company's revenue saw a modest increase of 2.1% year-on-year, reaching ₹168.90 crore. Despite a slight dip in EBITDA margin to 24.10%, RPG Life Sciences maintained a healthy profitability level. The Profit Before Tax (PBT) remained largely stable at ₹35.40 crore.

Segment Performance

• Domestic Formulations: This segment, contributing 69% to total sales, continued to deliver market-beating growth. The company reported improved salesforce productivity and successful implementation of its 5-pillar strategy.

• International Formulations: Accounting for 19% of total sales, this segment saw growth in new products, customers, and markets.

• API (Active Pharmaceutical Ingredients): Contributing 12% to total sales, this segment faced challenges due to a fire incident in one of the manufacturing blocks. However, the company continues to focus on new customer development and is driven by a 3-pillar strategy.

Management Commentary

Mr. Ashok Nair, Managing Director of RPG Life Sciences Ltd., commented on the results: "In Q1, we have sustained our sales growth momentum, reflecting the strength of our strategic execution and operational excellence. Our Domestic Formulations business continues to deliver market-beating growth, propelled by a focused transformation agenda and a customer-centric approach."

He added, "We remain firmly on track to accelerate both our International Formulations and API segments, with growth driven by rapid onboarding of new customers, strategic expansion into newer markets, and launch of newer molecules that broaden our therapeutic reach."

Future Outlook

RPG Life Sciences is actively exploring inorganic growth opportunities across both formulations and APIs to further accelerate its growth trajectory. The company's strategic initiatives, including the expansion into the OTC market and focus on immunosuppressants, are expected to drive future growth and create value for stakeholders.

With its multi-pronged approach focusing on domestic formulations, international markets, and API development, RPG Life Sciences appears well-positioned to capitalize on various growth opportunities in the pharmaceutical sector.

Corporate Updates

In a separate announcement, the company informed that Mr. Deepak Shukla has been appointed as Chief Executive - API Business, effective July 28. This appointment is expected to strengthen the leadership team and support the company's growth initiatives in the API segment.

As RPG Life Sciences continues to execute its strategic plans and navigate the evolving pharmaceutical landscape, investors and industry observers will be keenly watching the company's performance in the coming quarters.